Introduction
The herpes zoster virus (HZV), commonly known as shingles, is a debilitating condition caused by reactivation of the varicella zoster virus (VZV). The initial infection presents as chickenpox, which typically occurs during childhood, and is characterized by viremia with diffuse rash and seeding of multiple sensory ganglia where the virus establishes lifelong latency. 1 Although HZ can occur at any age, it is generally more prevalent and severe in older adults with higher rates of morbidity than seen in children and younger adults. 1, 2 There are more than one million cases of HZ each year in the United States. 3 According to claims data from a retrospective, observational, cohort study conducted in 2011, the annual incidence rate of HZ in immunocompetent adult patients was 4.47 per 12.49-13.07). 4 These findings are consistent with other literature supporting that the rate of HZ increases with age. 5 VZV reactivation increases with age due to a decline in immune response and a weakening of cell-mediated varicella virus specific T-cell activity over time. 6 Postherpetic neuralgia (PHN) is one of the most common and painful outcomes associated with HZ, and occurs in 10-50% of patients with age increasing risk. 1, 7 Antiviral therapy has been shown to reduce some of the symptoms associated with HZ including rash, but it has not been shown to reduce the incidence of PHN, further complications, or disease burden in older adults. 7 Vaccination against HZ has become standard care to reduce disease burden and its complications in older adults.
The purpose of this literature review is to investigate the effectiveness of HZ/su in 6 reducing the risk of HZ and PHN in older adults. 
Methods

Zoster vaccine live and HZ/su background information
Zoster vaccine live, an attenuated vaccine containing the Oka VZV strain, was the first FDA-approved method for HZ prevention in adults 50 years of age and older. 8, 9 It is administered as a one-time subcutaneous injection and must be given within 30 minutes of reconstitution. The mechanism of action of this vaccine is to boost the T-cell mediated immunity to VZV and thereby provide protection against HZ and PHN. It was first approved in May 2006 for use in patients 60 years of age and older. 10 In March 2011, the FDA extended its indication for use to individuals 50 to 59 years of age; however, the Advisory Committee on Immunization Practices (ACIP) denied to recommend the vaccine for this patient population based on limited data demonstrating protection beyond five years. 9 ACIP continues to recommend this vaccine for adults aged 60 years and older.
Several clinical trials of zoster vaccine live have previously been conducted. 9, [11] [12] [13] [14] [15] Results of the largest randomized, double-blind, placebo-controlled phase III trials, the Shingles Prevention Study (SPS) and the Zostavax Efficacy and Safety Trial (ZEST) can be found in Table 1 . 9, 11 Since zoster vaccine live has been shown to be less effective in older age groups, and the efficacy of the vaccine wanes over time, a new HZ vaccine with improved protection against HZ in older adults that provides longer postvaccination efficacy is needed.
HZ/su is a non-live herpes zoster subunit vaccine that incorporates VZV glycoprotein E (gE) and the AS01B adjuvant system. 18 VZV gE antigen was selected because it is the most abundant glycoprotein on both VZV virions and cells infected with VZV. In addition, it plays a crucial role in virus replication and cell-to-cell spread while demonstrating a greater immune response when compared to other glycoprotein antigens. 19 This antigen was combined with the AS01B adjuvant system because AS01B has been shown to enhance CD4 + T-cell and humoral immune response toward the recombinant protein complex, particularly in older adults. 16 HZ/su must be used within six hours of reconstitution. The dose (0.5 mL) should be administered intramuscularly into the deltoid muscle. HZ/su is a two-dose series, the second dose should be given two to six months following the first dose. 20 Each dose of HZ/su contains 50 µg of recombinant VZV gE and liposome-based AS01B adjuvant system containing 50 µg of 3-0-desacyl-4'-monophosphoryl lipid A (MPL) and 50 µg of Quillaja saponria Moilina, fraction 21. 16 ZOE-50 studied adults age 50 and older. 16 Participants were randomized 1:1 to receive HZ/su or placebo and stratified according to the following age groups: 50 to 59 years, 60 to 69 years, and 70 years and older. Each received two intramuscular doses of HZ/su, or placebo, two months apart. Notable exclusion criteria were history of HZ, prior vaccination again VZV or HZ, immunosuppression, receipt of immunoglobulin or blood product within the previous 90 days, receipt or planned administration of any other immunization prior to or during the study period, and pregnancy or lactation. The primary outcome was vaccine efficacy in reducing the risk of HZ in the modified vaccinated cohort. The modified vaccinated cohort included all participants who received two doses of vaccine and did not have a diagnosis of HZ within one month of the second dose; whereas, the total vaccinated cohort included all participants who had at least one dose of study vaccine administered. Secondary outcomes were vaccine efficacy in reducing the incidence of HZ in each stratified age group and HZ/su safety and reactogenicity profiles. Safety and reactogenicity were evaluated via diary cards in a subgroup of participants that included all those 70 years of age and older and randomly selected participants from the other two age groups. Serious AE were recorded in all subjects for 12 months following the second dose of HZ/su. Participants were followed for at least 30 months through monthly contacts and annual visits. 16 Total enrollment, demographic characteristics, and main efficacy and safety findings are available in Table 1 . Overall, HZ/su was found to reduce the risk of HZ by 97.2% (95% CI, 93.7-99.0) compared to placebo in the modified vaccinated cohort. Similarly, vaccine efficacy in the total vaccinated cohort overall was 96.2% (95% CI, 92.7-98.3) for HZ/su compared to placebo. No significant variations in vaccine efficacy between the agestratified groups in the modified vaccinated cohort were found. 16 Solicited safety and reactogenicity data reported for the subgroup are available in Table   2 ; grade 3 reactions are provided below. Grade 3 solicited injection site reactions were reported in 417 out of 4,382 subjects (9.5%) in the HZ/su subgroup participants compared to 16 out of 4,377 subjects (0.4%) in placebo subgroup participants, and grade 3 solicited systemic reactions were reported in 498 out of 4,375 (11.4%) of the HZ/su subgroup participants compared to 106 out of 4,378 (2.4%) in the placebo subgroup participants. Serious AE throughout the study period occurred in a similar percentage of vaccine and placebo recipients at 9.0% (689 out of 7,698) and 8.9% (686 out of 7,713) respectively. Immune-mediated diseases were observed in 1.0% (n = 78) in the vaccine group and in 1.3% (n = 97) in the placebo group. Moreover, death occurred in 2.2% (n = 167) of the vaccine group and 2.3% (n = 174) of the placebo group during the study. Final results at 60 months were reported in a pooled analysis with ZOE-70 participants and are discussed below. The authors concluded that HZ/su significantly reduced the risk of HZ in adults 50 years of age compared to placebo, with similar efficacy among the three age groups. No safety concerns were identified but solicited injection site reaction did occur more frequently in the HZ/su group. 16 ZOE-70 was a separate parallel study conducted over the same time period as ZOE-50. 17 Even though 24% of subjects enrolled in ZOE-50 were 70 years of age and older, the trial was not specifically powered to assess the efficacy of HZ/su in that oldest age group. Therefore, ZOE-70 was designed to evaluate vaccine efficacy in reducing the risk of HZ in adults 70 years of age and older. Participants were randomized in a 1:1 ratio to receive HZ/su or placebo and stratified according to continent and age (70 to 79 and ≥ 80 years). Each received two intramuscular doses of HZ/su or placebo two months apart. Study population as well as exclusion criteria were identical to that for ZOE-50 except for age. The primary outcome was vaccine efficacy in reducing the risk of HZ in patients 70 years of age and older via analysis of the modified vaccinated cohort. A pooled analysis including participants from ZOE-50 and ZOE-70 was conducted with the primary outcome of vaccine efficacy in reducing the risk of HZ and PHN in the overall population 70 years of age and older. The secondary outcomes for the pooled analysis were vaccine efficacy against PHN for patients age 50 and above and vaccine safety and reactogenicity. Safety and reactogenicity were evaluated in a subgroup via the same manner as in ZOE-50. Follow up for at least 30 months after the second vaccine dose via monthly contact in addition to annual clinic visits occurred. 17 Twenty-two percent (3,066 out of 13,900) of patients enrolled in ZOE-70 were ≥ 80 years of age; 0.5% (n = 76) were ≥ 90 years of years. Overall vaccine efficacy was 89.8% (95% CI, 84.2-93.7) for HZ/su as compared to placebo. There was no significant difference in vaccine efficacy between the two age groups, 90.0% (95% CI, 83.5-94. (n = 7,736), and 87.9% (95% CI, 73.3-95.4%) during year four (n = 7,426). Vaccine efficacy against PHN for the pooled modified vaccinated cohort of patients 50 years of age and older (n = 13,881) was 91.2% (95% CI, 75.9-97.7%). PHN did not develop in any participants younger than 70 years of age in the HZ/su group. Vaccine efficacy against PHN for ≥ 70 years was 88.8% (95% CI, 68.7-97.1). The incidence of PHN in recipients of HZ/su that experienced breakthrough HZ did not differ significantly from the placebo recipients [12.5% (n = 4) vs. 9.6% (n = 36), P= 0.54]. 14 Solicited safety and reactogenicity data reported for the subgroup can be found in Table   2 . Grade 3 solicited injection site reactions were reported in 43 out of 505 (8.5%) in the HZ/su subgroup participants compared to 1 out of 505 (0.2%) in placebo subgroup participants, and grade 3 solicited systemic reactions were reported in 30 out of 504 (6.0%) in the HZ/su subgroup participants compared to 10 out of 505 (2.0%) in the placebo subgroup participants. Grade 3 reactions were transient, lasting less than 48 hours. Serious AE throughout the study period occurred in a similar percentage of vaccine and placebo recipients at 16.6% (n = 1,153 out of 6,950) and 17.5% (n = 1,214 out of 6,950) respectively. Immune-mediated diseases were observed in 1.3% (n = 92) in the vaccine group and in 1.4% (n = 97) in the placebo group. Death occurred in 6.1% (n = 426) and 6.6% (n = 459) in the HZ/su and placebo groups respectively. One participant death in the HZ/su group was determined by the investigators to be related to study intervention. A 90-year-old with pre-existing thrombocytopenia was diagnosed with acute myeloid leukemia 75 days after receipt the first HZ/su dose and died at 97 days after that dose due to neutropenic sepsis. The authors concluded that HZ/su reduced the risk of HZ and PHN in adults 70 years of age and older with no substantial concerns for safety. Results of ZOE-70 are consistent with results from ZOE-50.
Authors caution that deductions regarding a potential lack of decline in efficacy of HZ/su over time cannot be made until additional follow up over a longer period becomes available. 14 While ZOE-50 and ZOE-70 were large, multicenter trials with a randomized, placebocontrolled design, there are a few limitations to note. First, the number of participants that developed PHN was very low, none under 70 years of age, so there was limited power to evaluate the efficacy of HZ/su in reducing the risk of PHN overall. The reported decline in PHN cannot be directly supported by the study data but seems to be a result of the notable efficacy of HZ/su in preventing HZ reactivation. Second, mean follow up time was 3.2 and 3.7 years respectively; evidence that vaccine efficacy persists over a longer duration is needed. Finally, the studies excluded those with a history of HZ, previous varicella or zoster vaccination, immunosuppression, and pregnancy. These patient populations may benefit from an adjuvanted vaccine since zoster vaccine live is contraindicated in these situations.
The studies summarized below all utilized increases in HZV-specific anti-gE antibodies as endpoints. VZV gE is the most abundant glycoprotein in VZV viral particles and cells infected with VZV. VZV gE plays a central role in virus infectivity, cell-to-cell spread, and progression of the infection. 21 Therefore anti-gE antibodies are thought to be predictors of disease. The threshold at which anti-gE antibody response correlates to disease prevention is unclear so the use of this surrogate marker predicts immune response to HZ/su but has not been quantitatively correlated to disease prevention. 
Use in patients with HIV
The safety and immunogenicity of HZ/su in HIV-infected adults was evaluated in a randomized, observer-blinded, placebo-controlled multicenter phase 1/2a study. 24 Eligible subjects had a diagnosis of HIV for at least a year. Those with an episode of VZV or HZ or receipt of vaccination against either virus within the prior 12 months; ongoing treatment with HIV fusion inhibitors, CCR5 inhibitors, or interleukin 2/interleukin 7/interferon gamma; or an opportunistic infection other than oral thrush within the previous year were excluded. It was unknown whether the standard two-dose regimen would elicit a favorable immune response in HIV-infected individuals, therefore three doses were administered and immunogenicity was evaluated after doses two and three.
The co-primary objectives were to evaluate gE-specific humoral and cellular immune responses one month following the third vaccination in the HZ/su group compared to the placebo group, and safety and reactogenicity. Serious AE, new onset of immunemediated inflammatory diseases, worsening HIV, and HZ were reported throughout the study. Subjects were randomized in a 3:2 ratio to receive HZ/su or placebo at months zero, two, and six. 24 Three cohorts of HIV-infected adults were enrolled: 94 with a CD4 + count of ≥ 200 cells/mm 3 or immunoglobulins since transplantation, and woman of childbearing potential. The study compared four groups, one placebo group and three separate active treatment groups. In the first active arm subjects received three doses of 50 µg gE + AS01B, in the second subjects received three doses of 50 µg gE + AS01E, and in the third subjects received one dose of saline followed by two doses of 50 µg VZV gE + AS01B. Study vaccine was administered at months zero, one, and three. The co-primary objectives were to examine the safety and immunogenicity of the two adjuvanted gE subunit vaccine formulations (AS01B and AS01E) in the autologous HCT population and to compare gE-specific immune responses one month following final vaccination between the four groups. Recurrence of underlying malignancy and new onset autoimmune disease or immune-mediated inflammatory disorders were recorded for the duration of the study. Participants were randomized 1:1:1:1. 25 A total of 121 participants were enrolled. Median participant age was 59.0 years (range 20-70), 65% were male, and 83.3% were White. One month after receipt of the final dose, cellular and humoral immune responses were higher in all three gE/AS01 groups compared to placebo (p< 0.0001 for all comparisons). Although there were no statistical differences in immunity between the AS01B and AS01E groups, AS01B tended to be more immunogenic. Immune responses persisted up to one year post-vaccination. 25 Most subjects in the HZ/su groups experienced solicited local and general reactions.
Pain at the injection site was the most commonly reported local reaction (75.9-90.0% in the three groups which received HZ/su compared to 13.3-23.3% in placebo recipients) while myalgia (62.1-78.6% in the HZ/su recipients compared to 26.7-30% in placebo recipients) was the most commonly reported general reaction. One serious AE was potentially related to the vaccination according to the study investigator. It was pneumonia which occurred 105 days after the second dose in the gE/AS01B two-dose group. Malignancy recurred in 32 subjects. No new onset autoimmune diseases or immune-mediated inflammatory diseases were reported. Although there were nine deaths during the study period none were considered to be related to vaccination.
Throughout the study, four cases of HZ were confirmed, two in the gE/AS01E group and two in the placebo group. Five subjects withdrew from the study due to serious AE.
Authors' conclusions were that both adjuvanted vaccine formulations and both AS01B schedules were immunogenic and well tolerated soon after HCT in this immunocompromised patient population. The vaccine may be a suitable candidate to reduce HZ burden in autologous HCT recipients. 25 
Current regulatory status
On October 24, 2016, GSK Vaccines Division announced regulatory submission of a Biologics License Application for the candidate vaccine HZ/su (Shingrix TM ). 10 GSK also filed a marketing authorization application in the European Union and Canada in 2016 and in Japan in April 2017. [26] [27] In early October 2017, HZ/su was approved in Canada for the prevention of HZ in adults 50 years of age and older. 28 On October 20, 2017, the FDA approved HZ/su for the prevention of HZ in adults aged 50 years and older. 29 The CDC's ACIP subsequently voted to recommend HZ/su to prevent HZ and related complications in immunocompetent adults aged 50 years and older, including those who were previously vaccinated with zoster vaccine live. Furthermore, the group voted to prefer HZ/su over zoster vaccine live moving forward. 30 
Discussion
Studies summarized above have shown that HZ/su effectively decreases the risk of HZ (overall vaccine efficacy in reported phase III trials ranged from 89.8-97.2%) in older patients, including those > 80. 16, 17, 22 Available evidence has not shown a substantial decline in immune response to HZ/su in older age over time (97.6% in year one to 87.9% in year four following administration) but longer-term evaluation is needed. 17 PHN is considered to be a large burden associated with HZ, especially in older patients.
All patients that developed PHN in pooled data from ZOE-50 and ZOE-70 were over the age of 70, but the incidence was low. 17 The overall risk of PHN was reduced in patients who received HZ/su, but the protective effect against PHN may have been driven by the lower overall incidence of HZ due to high vaccine efficacy. There is no evidence for additional efficacy for the vaccine against PHN among HZ/su recipients who had breakthrough HZ, but the overall risk of developing PHN among older adults was substantially reduced.
While no direct head-to-head trials evaluating vaccine efficacy of HZ/su compared to zoster vaccine live have been published to date, in separate phase III trials, HZ/su seems to have better efficacy in those older than 70 years of age, higher efficacy for the prevention of PHN, and potentially longer persistence of immunogenicity. However, direct comparison of efficacy results of HZ/su and zoster vaccine live in phase III clinical trials is difficult as the primary endpoints were different for the trials. A head-to-head trial comparing HZ/su to zoster vaccine live in individuals 50-59 and 70-85 years of age is ongoing (NCT02114333). 31 The results will provide greater insight in determining differences in efficacy between HZ/su and zoster vaccine live.
When compared to placebo, reactogenicity of HZ/su was greater in all studies. Although pain at the injection site was the most common solicited AE reported in the HZ/su treatment groups, most reactions were transient and considered to be mild to moderate in nature. 16, 17, 22 Safety data demonstrated no significant differences in rates of vaccinerelated serious AE or death between HZ/su and placebo.
Place in therapy
Newly approved by the FDA, HZ/su is expected to have an expanded role in therapy compared to zoster vaccine live and is being endorsed by the ACIP as the preferred vaccination against HZ. Because HZ/su is a two dose series, completion of the second dose will need to be reinforced.
The efficacy and safety of HZ/su in immunocompromised patients has been demonstrated in two small studies with limited patient populations but additional trials are ongoing. A placebo-controlled, phase III trial examining the efficacy and safety of a two-dose schedule of HZ/su in adults following HCT has completed enrollment and is awaiting results (NCT01610414). 32 Another placebo-controlled, phase III trial is evaluating the use of HZ/su in adult renal transplant patients (NCT02058589). 33 The 22 results of these studies may lead to approval of HZ/su for immunocompromised populations where a gap in protection currently exists.
Conclusion
The risk and severity of HZ increase with age and immunosuppression. Zoster vaccine live has been available for over a decade. However, it has limitations including lower efficacy in patients older than 60 years, a decline in efficacy over time, and a contraindication in immunocompromised patients. HZ/su is a new and preferred option to reduce the risk of HZ and PHN in patients 50 years of age and older. It has advantages over zoster vaccine live and in the future may be appropriate for immunosuppressed patients. 
